Limits...
Enhancing effects of indirubin on the arsenic disulfide-induced apoptosis of human diffuse large B-cell lymphoma cells.

Wang L, Li X, Liu X, Lu K, Chen NA, Li P, Lv X, Wang X - Oncol Lett (2015)

Bottom Line: The qPCR results revealed that indirubin alone had no enhancing effect upon the Bax/Bcl-2 mRNA expression ratio and caspase-3 mRNA expression.However, the combination of indirubin and As2S2 yielded enhancing effects.The enhancing effect was due, in part, to the induction of the mitochondrial apoptotic pathway, which involves the cleavage of Bax.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China ; Department of Hematology, Taian City Central Hospital, Tai'an, Shandong 271000, P.R. China.

ABSTRACT

The aim of the present study was to investigate the indirubin-enhanced effects of arsenic disulfide (As2S2) on the proliferation and apoptosis of diffuse large B-cell lymphoma (DLBCL) cells in order to identify an optimum combination therapy. The human DLBCL cells, LY1 and LY8, were treated with different concentrations of indirubin for 24, 48 and 72 h. Next, the cells were treated with 10 μM As2S2 or a combination of 10 μM As2S2 and 20 μM indirubin for 48 h. Cell proliferation inhibition was detected using cell counting kit-8 and cell apoptosis was determined using flow cytometry. The expression levels of Bcl-2, Bcl-2-associated X protein (Bax) and caspase-3 were analyzed by quantitative polymerase chain reaction (qPCR) and western blotting. The DLBCL cell viability exhibited no significant changes at 24, 48 or 72 h with increasing indirubin concentration. In addition, the apoptotic rates of the LY1 and LY8 cells demonstrated no noticeable effects at 48 h with increasing indirubin concentration. Following treatment with the combination of indirubin and As2S2, the inhibitory and apoptotic rates of the cells were notably increased compared with those of the As2S2-treated group. The qPCR results revealed that indirubin alone had no enhancing effect upon the Bax/Bcl-2 mRNA expression ratio and caspase-3 mRNA expression. Western blot analysis revealed that indirubin alone had an enhancing effect upon the Bax/Bcl-2 protein ratio and procaspase-3 protein expression. In addition, the results demonstrated that the 21-KDa Bax protein was proteolytically cleaved into an 18-KDa Bax in the DLBCL cells treated with the combination of indirubin and As2S2. Indirubin alone did not inhibit proliferation or induce the apoptosis of the LY1 and LY8 cells. However, the combination of indirubin and As2S2 yielded enhancing effects. Therefore, the results of the present study demonstrated that with regard to antitumor activities, As2S2 served as the principal drug, whereas indirubin served as the adjuvant drug. The enhancing effect was due, in part, to the induction of the mitochondrial apoptotic pathway, which involves the cleavage of Bax.

No MeSH data available.


Related in: MedlinePlus

Effects of indirubin and arsenic disulfide (As2S2), alone or in combination, on the transcription levels of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and caspase-3 genes in diffuse large B-cell lymphoma cells. The relative mRNA levels of Bax, Bcl-2 and caspase-3 genes were assessed by quantitative polymerase chain reaction following treatment with 10 μM As2S2 and 20 μM indirubin, alone or in combination, for 48 h in (A) LY1 and (B) LY8 cells. Values are expressed as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. untreated control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4356417&req=5

f4-ol-09-04-1940: Effects of indirubin and arsenic disulfide (As2S2), alone or in combination, on the transcription levels of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and caspase-3 genes in diffuse large B-cell lymphoma cells. The relative mRNA levels of Bax, Bcl-2 and caspase-3 genes were assessed by quantitative polymerase chain reaction following treatment with 10 μM As2S2 and 20 μM indirubin, alone or in combination, for 48 h in (A) LY1 and (B) LY8 cells. Values are expressed as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. untreated control.

Mentions: Our previous study demonstrated that As2S2-induced apoptosis was dependent upon the mitochondrial-mediated apoptosis pathway (21). In order to investigate whether the combination treatment led to enhancement of the mRNA levels of the Bax, Bcl-2 and caspase-3 genes, qPCR was performed. As shown in Fig. 4, no significant differences in the expression of the Bax, Bcl-2 and caspase-3 genes in the DLBCL cells were observed between the As2S2 group and the combination group.


Enhancing effects of indirubin on the arsenic disulfide-induced apoptosis of human diffuse large B-cell lymphoma cells.

Wang L, Li X, Liu X, Lu K, Chen NA, Li P, Lv X, Wang X - Oncol Lett (2015)

Effects of indirubin and arsenic disulfide (As2S2), alone or in combination, on the transcription levels of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and caspase-3 genes in diffuse large B-cell lymphoma cells. The relative mRNA levels of Bax, Bcl-2 and caspase-3 genes were assessed by quantitative polymerase chain reaction following treatment with 10 μM As2S2 and 20 μM indirubin, alone or in combination, for 48 h in (A) LY1 and (B) LY8 cells. Values are expressed as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. untreated control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4356417&req=5

f4-ol-09-04-1940: Effects of indirubin and arsenic disulfide (As2S2), alone or in combination, on the transcription levels of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and caspase-3 genes in diffuse large B-cell lymphoma cells. The relative mRNA levels of Bax, Bcl-2 and caspase-3 genes were assessed by quantitative polymerase chain reaction following treatment with 10 μM As2S2 and 20 μM indirubin, alone or in combination, for 48 h in (A) LY1 and (B) LY8 cells. Values are expressed as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. untreated control.
Mentions: Our previous study demonstrated that As2S2-induced apoptosis was dependent upon the mitochondrial-mediated apoptosis pathway (21). In order to investigate whether the combination treatment led to enhancement of the mRNA levels of the Bax, Bcl-2 and caspase-3 genes, qPCR was performed. As shown in Fig. 4, no significant differences in the expression of the Bax, Bcl-2 and caspase-3 genes in the DLBCL cells were observed between the As2S2 group and the combination group.

Bottom Line: The qPCR results revealed that indirubin alone had no enhancing effect upon the Bax/Bcl-2 mRNA expression ratio and caspase-3 mRNA expression.However, the combination of indirubin and As2S2 yielded enhancing effects.The enhancing effect was due, in part, to the induction of the mitochondrial apoptotic pathway, which involves the cleavage of Bax.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China ; Department of Hematology, Taian City Central Hospital, Tai'an, Shandong 271000, P.R. China.

ABSTRACT

The aim of the present study was to investigate the indirubin-enhanced effects of arsenic disulfide (As2S2) on the proliferation and apoptosis of diffuse large B-cell lymphoma (DLBCL) cells in order to identify an optimum combination therapy. The human DLBCL cells, LY1 and LY8, were treated with different concentrations of indirubin for 24, 48 and 72 h. Next, the cells were treated with 10 μM As2S2 or a combination of 10 μM As2S2 and 20 μM indirubin for 48 h. Cell proliferation inhibition was detected using cell counting kit-8 and cell apoptosis was determined using flow cytometry. The expression levels of Bcl-2, Bcl-2-associated X protein (Bax) and caspase-3 were analyzed by quantitative polymerase chain reaction (qPCR) and western blotting. The DLBCL cell viability exhibited no significant changes at 24, 48 or 72 h with increasing indirubin concentration. In addition, the apoptotic rates of the LY1 and LY8 cells demonstrated no noticeable effects at 48 h with increasing indirubin concentration. Following treatment with the combination of indirubin and As2S2, the inhibitory and apoptotic rates of the cells were notably increased compared with those of the As2S2-treated group. The qPCR results revealed that indirubin alone had no enhancing effect upon the Bax/Bcl-2 mRNA expression ratio and caspase-3 mRNA expression. Western blot analysis revealed that indirubin alone had an enhancing effect upon the Bax/Bcl-2 protein ratio and procaspase-3 protein expression. In addition, the results demonstrated that the 21-KDa Bax protein was proteolytically cleaved into an 18-KDa Bax in the DLBCL cells treated with the combination of indirubin and As2S2. Indirubin alone did not inhibit proliferation or induce the apoptosis of the LY1 and LY8 cells. However, the combination of indirubin and As2S2 yielded enhancing effects. Therefore, the results of the present study demonstrated that with regard to antitumor activities, As2S2 served as the principal drug, whereas indirubin served as the adjuvant drug. The enhancing effect was due, in part, to the induction of the mitochondrial apoptotic pathway, which involves the cleavage of Bax.

No MeSH data available.


Related in: MedlinePlus